Strategic Acquisition Leverage ACell’s integration with Integra LifeSciences to position complementary wound care and regenerative tissue solutions to customers already aligned with Integra’s broad product portfolio, highlighting cross-sell opportunities across UBM, Cytal, MicroMatrix, and Gentrix lines.

Growth & Global Reach Target hospital systems and distribution partners that benefit from Integra’s global footprint and multi-brand strategy to expand adoption of ACell’s UBM-based matrices, leveraging existing relationships and supply chains.

Regulatory & Leadership Signals Capitalize on new regulatory leadership and ongoing corporate governance activity at Integra to time targeted outreach for product launches, regulatory clearances, and market access upgrades aligned with leadership priorities.

Clinical & Market Trends Align with rising demand in soft tissue repair, wound care, burns, and reconstructive procedures by promoting Cytal, Gentrix, and MicroMatrix platforms as integrated regenerative solutions for higher patient outcomes and hospital efficiency.

Operational Strength Position offerings as part of a reliability-driven supply strategy, emphasizing Integra’s improved supply chain and manufacturing execution to reduce stockouts and improve procurement planning for UBM-based products.